This clinical trial is focused on studying the effects of a medication called sotagliflozin in people with Type 1 Diabetes Mellitus who also have chronic kidney complications. The purpose of the study is to understand how this medication might help in preventing the progression of chronic kidney disease (CKD) in these patients. Sotagliflozin is a type of drug known as a dual inhibitor of SGLT1 and SGLT2, which means it works by blocking certain proteins in the body that are involved in sugar absorption and kidney function.

Participants in the study will receive either sotagliflozin or a placebo, which is a tablet that looks like the medication but does not contain the active drug. The study will last for about three months, during which the effects of the medication on kidney health will be monitored. This will be done using a special imaging technique called MRI (Magnetic Resonance Imaging) to measure how well the kidneys are being supplied with oxygen. The goal is to see if sotagliflozin can improve kidney oxygenation compared to the placebo.

The study aims to provide valuable insights into how long-term use of sotagliflozin might help manage kidney health in people with Type 1 Diabetes and chronic kidney disease. By understanding these effects, researchers hope to find better ways to support kidney function and slow down the progression of kidney disease in these patients.